LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates a significant net loss increase, with a widening loss per share, which is a negative sign. Despite some positive signals in product adoption and marketing strategies, the lack of specific data on important metrics and the deferral of detailed refill metrics suggest uncertainties. The management's optimistic guidance on DTC efforts and sales force expansion is tempered by the potential delay in seeing results. Overall, the negative financial performance and uncertainties in execution outweigh the positive aspects, leading to a likely negative stock price reaction.
Key Financial Performance
Cash and Cash Equivalents $292.3 million at the end of 2025, representing significant financial strength.
Net Product Revenues $1.6 million in Q4 2025, driven by over 20,000 monthly paid and filled prescriptions.
Operating Expenses $40 million in Q4 2025, including $4 million of noncash stock-based compensation expense, up from $31.4 million in Q3 2025. Increase driven by commercial strategy and launch of VIZZ.
Cost of Goods Sold $400,000 in Q4 2025, primarily driven by indirect product costs associated with nonrecurring manufacturing processes.
SG&A Expenses $39.6 million in Q4 2025, up from $27.6 million in Q3 2025, driven by sales force establishment and DTC campaign launch.
R&D Expenses $0 in Q4 2025, down from $5.9 million in Q4 2024, due to the conclusion of the Phase III CLARITY study and VIZZ approval.
Net Loss $35.9 million in Q4 2025, compared to $12.7 million in Q4 2024. Loss per share was $1.16 in Q4 2025, compared to $0.46 in Q4 2024.
Gross to Net Ratio Approximately 90% or $67 per monthly package of VIZZ, with net cash per unit of $60 per monthly package.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Product Launch: LENZ Therapeutics launched VIZZ, a once-daily eye drop for presbyopia, which has shown promising results in clinical trials and real-world applications. The product works quickly, with effects noticeable within 30 minutes and lasting throughout the workday.
Sales Performance: Over 45,000 boxes of VIZZ have been sold, prescribed by more than 10,000 eye care professionals. The product is generating encouraging refill behavior and has a broad patient profile.
Consumer Campaign: A direct-to-consumer campaign featuring Sarah Jessica Parker has been launched, driving significant engagement with website traffic increasing up to 10x during activations.
Market Opportunity: Presbyopia affects approximately 128 million people in the U.S., presenting a large and underpenetrated market opportunity for VIZZ.
Global Expansion: LENZ has initiated regulatory submissions in multiple countries, including China, South Korea, Thailand, Singapore, and Europe, with potential approvals expected in 2027.
Sales Force Expansion: The sales force has been expanded from 88 to 117 representatives to increase call frequency and cover more eye care professionals.
Physician Engagement: Efforts are focused on helping physicians integrate VIZZ into routine exams and addressing misconceptions about its target patient population.
Category Creation: LENZ is building a new treatment category for presbyopia, focusing on long-term patient retention and gradual adoption rather than rapid initial uptake.
Financial Strength: The company ended 2025 with $292.3 million in cash, enabling continued investment in product launch and market expansion.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Commercial Plans: The company acknowledges the risks associated with forward-looking statements, including regulatory hurdles and commercial plans, as highlighted in their SEC filings.
Market Adoption: The launch of a new treatment category is inherently challenging, requiring time to develop prescribing habits among eye care professionals and consumer awareness. This gradual adoption could impact the pace of revenue growth.
Physician Engagement: Eye care professionals need to integrate the product into their practice, which requires overcoming unfamiliarity and changing prescribing habits. This could slow down adoption rates.
Consumer Awareness: Building consumer awareness for a new product category takes time, with direct-to-consumer campaigns typically requiring at least two quarters to translate into prescription trends.
Sales Force Expansion: The company is expanding its sales force to 117 representatives, which involves significant investment and operational challenges to ensure effective coverage and engagement.
Financial Sustainability: The company reported a net loss of $35.9 million in Q4 2025, with a cash burn of $32 million. While they have significant cash reserves, sustained losses could pose financial risks if revenue growth does not accelerate.
Global Expansion: International regulatory approvals and commercialization efforts are underway but could face delays or challenges, impacting the timeline for global revenue generation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections: The company expects a gradual ramp in new patient adoption and an acceleration in new patient starts as prescribing habits build and consumer awareness grows. Early signals from the direct-to-consumer campaign are encouraging, with a more meaningful impact on prescription trends anticipated in the second half of the year.
Market Trends and Growth Expectations: LENZ Therapeutics is building a new treatment category for presbyopia, targeting a large and underpenetrated market of 128 million presbyopes in the United States. The company anticipates significant growth potential as the category develops and adoption accelerates.
Operational Changes and Strategic Plans: The company is expanding its field organization from 88 to 117 representatives to increase call frequency with existing prescribers and broaden the reach to approximately 15,000 eye care professionals. This expansion is expected to be fully onboarded in Q2 2026. Additionally, LENZ is optimizing its direct-to-consumer campaign to drive consumer awareness and demand, with plans to pilot linear TV commercials in select markets starting in April 2026.
Global Expansion: LENZ is advancing the global expansion of its product, VIZZ, with regulatory submissions completed in five countries and plans for over ten submissions by the end of 2026. Multiple potential approvals are anticipated in early 2027.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the sampling dynamic to NRx and refill tracking to internal expectations?
A:Management feels positive about the adoption of the product, with over 10,000 prescribing ECPs and more than 45,000 boxes sold. Early signals indicate that patients are reordering, moving from 1-month packs to 3-month packs, and new patients are starting with multi-month supplies. The sampling strategy appears effective, and the patterns align with expectations.
Q:What investments are being made to broaden patient demand, and will television advertising lift prescriptions within two quarters?
A:Investments focus on digital advertising, targeting specific demographics, and optimizing media placements. Linear TV ads are being tested in select markets to drive adoption. Management expects DTC efforts to take at least two quarters to show results, with early indicators like increased web traffic being positive.
Q:What percentage of prescriber additions are from the initial target group versus patient demand imbalance?
A:The field team initially targeted 12,000 ECPs and has expanded to 15,000 due to lower decile prescribers and new doctors showing interest. The expansion of the sales force from 88 to 117 reps allows for more frequent engagement with prescribers.
Q:Can you elaborate on the behavior of the top 1,000 writers and how to correct misconceptions about the product's target audience?
A:Top prescribers are writing 40% more scripts and have figured out how to quickly and effectively offer the product to patients. Misconceptions stem from the previous product's limited efficacy in early presbyopes. Management is working to educate prescribers about the broader applicability of the product.
Q:Are TV ads replacing the focus on digital and influencer marketing?
A:No, the strategy remains focused on digital ads and influencers. TV ads are being tested in select markets to complement the existing strategy. Management is monitoring web traffic and script conversions to evaluate effectiveness.
Q:Which patient segments are driving early adoption, and what is the distribution channel mix?
A:Early adopters include contact lens wearers, post-refractive surgery patients, and those with active lifestyles. About half of patients have worn contacts, one-third had LASIK, and one-fourth used BOTOX. Both e-pharmacy and retail channels are meaningful, but the mix has not been disclosed.
Q:What is the split between 1-month and 3-month packs, and do early adopters align with refill projections?
A:Management has not disclosed the exact split but notes a shift towards 3-month packs. Early adopters are showing encouraging refill behavior, but detailed metrics will be shared in the second half of the year.
Q:How many samples in Q4 converted to scripts in Q1?
A:Management has not disclosed specific conversion rates but notes that over 90% of new patients start with a sample. Sampling is seen as cost-effective and essential for patient self-selection.
Q:What indicators are most encouraging regarding the DTC program, and what thresholds are expected in Q2?
A:Encouraging indicators include increased web traffic (up to 10x in some cases) and better-than-benchmark click-through rates. Management expects DTC and sales force expansion to drive patient activation, with more significant results anticipated in the second half of the year.
Q:What are the nuances in initial refill patients, and are early presbyopes predominant?
A:Refill patients align with target demographics, including 60% women, 40% men, and a majority aged 55-64. Early adopters include contact lens wearers and post-refractive surgery patients, consistent with the target audience.
Q:How often are doctors giving out samples, and what is the time to become a repeat prescriber?
A:Most doctors are handing out samples, with over 90% of new patients starting with one. Some doctors prefer to write scripts directly. Prescribing dynamics vary, with some doctors quickly becoming repeat prescribers and others taking longer.
Q:Review of Unclear Management Responses
A:Management avoided providing specific data on the split between 1-month and 3-month packs, the exact mix of e-pharmacy and retail channels, and the conversion rate of Q4 samples to Q1 scripts. They also deferred sharing detailed refill metrics until the second half of the year, citing the need for more data over multiple quarters.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Agency
Eef
TV commercial
VUITY
activation
adoption field
allocation medium
audience
awareness consumer
base
behavior
benchmark
benefit
blockbuster
breadth
capital allocation
care product
category consumer
consumer awareness
country
exam
expansion
foundation
frequency
investment
mix
month launch
network
patient refill
persistence
physician
presbyope
prescriber
prescribing habit
product launch
ramp
reach
signal
stage launch
treatment category
trend
volume
LENZ Transcript
LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript
Unknown5-11
The earnings call presents a mixed picture: strong early signals from consumer campaigns and a large market potential are positive, but the company's financials show a significant net loss and increased expenses. The Q&A highlights management's focus on consumer awareness and product efficacy, yet lacks clarity on some critical operational details. The absence of R&D spending could be concerning. Without clear guidance or a strong financial performance, the stock price is likely to remain stable over the next two weeks, resulting in a neutral sentiment.
LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call indicates a significant net loss increase, with a widening loss per share, which is a negative sign. Despite some positive signals in product adoption and marketing strategies, the lack of specific data on important metrics and the deferral of detailed refill metrics suggest uncertainties. The management's optimistic guidance on DTC efforts and sales force expansion is tempered by the potential delay in seeing results. Overall, the negative financial performance and uncertainties in execution outweigh the positive aspects, leading to a likely negative stock price reaction.
LENZ Therapeutics, Inc. (LENZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Neutral12-4
LENZ Therapeutics, Inc. (LENZ) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call summary indicates a mix of positive and cautious elements. Strong early sales of VIZZ and positive initial feedback are promising, but management's reluctance to provide detailed guidance or conversion rates tempers enthusiasm. While the marketing strategy and spokesperson choice are well-received, the lack of specific prescription trends and financial guidance suggests uncertainty. The neutral sentiment reflects this balance of optimism and caution.
LENZ Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
